Leaders of the U.S. House Oversight Committee are demanding more documents from Mylan regarding its EpiPen autoinjector, following questions about whether CEO Heather Bresch tried to mislead lawmakers about how much profit the EpiPen brings in.
Ms. Bresch testified at a Sept. 21 hearing that Mylan makes about $100 on each EpiPen two-pack that lists for around $600.
The committee later learned that the company presented profit figures that were calculated after deducting taxes, and it used the statutory U.S. tax rate of 37.5 percent — a much higher rate than Mylan actually pays. According to Mylan’s financial reports, the company’s overall tax rate was 7.4 percent in 2015.
“Neither your testimony, nor the documents Mylan produced to the committee, clearly disclosed” that profits were calculated after taxes, Reps. Jason Chaffetz and Elijah Cummings wrote in a letter to the CEO released Monday.
“Failing to disclose tax assumptions that formed the basis for the $100 profit-per-pack claim, despite opportunities to do so before and during the hearing, raises questions,” the letter said.
2016 09 30 JEC EEC to Bresch Mylan EpiPen Follow Up Due 10 7 (PDF)
2016 09 30 JEC EEC to Bresch Mylan EpiPen Follow Up Due 10 7 (Text)
Mylan, which has its executive offices in Cecil, has come under intense scrutiny by state officials and on Capitol Hill following an outcry from consumers over a more than 500 percent hike in the price of the potentially lifesaving allergy device in recent years. The issue has further fueled a national debate about the escalating cost of prescription drugs.
During the hearing, lawmakers had repeatedly asked Ms. Bresch to explain the company’s profit calculations, saying the figures didn’t make sense.
“You know, your numbers don’t add up. ... And it’s extremely difficult to believe that you are making only $50 [per pen] profit,” Mr. Cummings told Ms. Bresch. Mr. Chaffetz called the presentation “dumbed down.”
A few days after the hearing, Mylan defended the $50-per-pen profit figure, unveiling additional details about its calculations in a filing with the U.S. Securities and Exchange Commission that it also then provided to the oversight committee. The company has called its analysis using the statutory tax rate “standard.”
In their letter released Monday, Mr. Chaffetz and Mr. Cummings gave Mylan an Oct. 7 deadline to produce a range of new documents, including “internal analyses or memoranda” relating to EpiPen sales, profits and costs; all documents Ms. Bresch relied on to prepare for the Sept. 21 hearing; and documents showing the actual tax rate and amount of taxes paid to the Internal Revenue Service each year since Mylan acquired rights to the EpiPen in 2007.
The committee also asked the company to identify all employees who have worked with the government regarding the classification of the EpiPen under the federal Medicaid Drug Rebate Program.
Mylan is facing questions about whether it shortchanged the Medicaid program by underpaying state rebates for the EpiPen.
Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.